abstract |
A long-acting antiparasitic formulation suitable for topical application including: (a) 0.1-50% w/v an avermectin or milbemycin having activity against endo- and/or ectoparasites; (b) 1-50% v/v a di(C2-4 glycol) mono(C1-4 alkyl) ether; (c) an optional antioxidant; and (d) an optional skin acceptable volatile solvent q.s. v/v. An antiparasitic formulation wherein the formulation consists of (a) 5-oximino-22,23-dihydro-25-cyclohexylavermectin B1 monosaccharide (selamectin, at a level of 1% to 16% w/v); (b) DPGMME at 1 to 16% v/v, and at a w/v to v/v ratio of active compound to DPGMME of about 1:1; (c) isopropanol q.s. 100% v/v; and, optionally (d) BHT (at less than 0.1% w/v). |